Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Matinas BioPharma Holdings, Inc.MTNB · Entity 8443 | See Remarks | March 01, 2017 | March 01, 2017 |
| NewAmsterdam Pharma Co N.V.NAMS · Entity 1826 | Chief Operating Officer | July 15, 2025 | July 17, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Matinas BioPharma Holdings, Inc.
Report date March 01, 2017 · Filed March 01, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.0001 per shareSEC Table I · non-derivative | Direct | 80,000 |
Reported balance
Holding disclosure · report date 2017-03-01 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 80,000 |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.52 · Expires 2025-03-11 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2017-03-01 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F1: The option award was made in accordance with the terms of the issuer's Matinas BioPharma Holdings, Inc. Amended and Restated 2013 Equity Incentive Plan (the "2013 Plan"). The option vests in equal monthly installments over a period of 36 months commencing on March 12, 2015. The exercise price is based on the average of the closing bid and asked prices for the shares of the Common Stock on the OTC.QB on the date of grant in accordance with the terms of the 2013 Plan. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.43 · Expires 2026-02-14 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2017-03-01 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance Not disclosed F2: The option award was made in accordance with the terms of the issuer's Matinas BioPharma Holdings, Inc. Amended and Restated 2013 Equity Incentive Plan. The option vests in equal monthly installments over a period of 36 months commencing on February 15, 2016. The exercise price is based on the average of the closing bid and asked prices for the shares of the Common Stock on the OTC.QB on the date of grant in accordance with the terms of the 2013 Plan. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.32 · Expires 2027-02-20 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2017-03-01 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance Not disclosed F3: The option award was made in accordance with the terms of the issuer's Matinas BioPharma Holdings, Inc. Amended and Restated 2013 Equity Incentive Plan. The option vests in equal monthly installments over a period of 36 months commencing on February 21, 2017. The exercise price is based on the average of the closing bid and asked prices for the shares of the Common Stock on the OTC.QB on the date of grant in accordance with the terms of the 2013 Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: The option award was made in accordance with the terms of the issuer's Matinas BioPharma Holdings, Inc. Amended and Restated 2013 Equity Incentive Plan (the "2013 Plan"). The option vests in equal monthly installments over a period of 36 months commencing on March 12, 2015. The exercise price is based on the average of the closing bid and asked prices for the shares of the Common Stock on the OTC.QB on the date of grant in accordance with the terms of the 2013 Plan.
F2: The option award was made in accordance with the terms of the issuer's Matinas BioPharma Holdings, Inc. Amended and Restated 2013 Equity Incentive Plan. The option vests in equal monthly installments over a period of 36 months commencing on February 15, 2016. The exercise price is based on the average of the closing bid and asked prices for the shares of the Common Stock on the OTC.QB on the date of grant in accordance with the terms of the 2013 Plan.
F3: The option award was made in accordance with the terms of the issuer's Matinas BioPharma Holdings, Inc. Amended and Restated 2013 Equity Incentive Plan. The option vests in equal monthly installments over a period of 36 months commencing on February 21, 2017. The exercise price is based on the average of the closing bid and asked prices for the shares of the Common Stock on the OTC.QB on the date of grant in accordance with the terms of the 2013 Plan.
NewAmsterdam Pharma Co N.V.
Report date July 15, 2025 · Filed July 17, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 44,000 |
Ending reported balance
After 2025-07-16 transaction · row 5
5 source rows · reconciled sequenceRow 1 · 2025-07-15 · Exercise / conversion · Acquired 47,569 · Balance 91,569 Row 2 · 2025-07-15 · Sale · Disposed 44,025 · Balance 47,544 F1: This transaction was effected pursuant to a trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.02 per share to $22.01 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction. Row 3 · 2025-07-15 · Sale · Disposed 3,544 · Balance 44,000 F1: This transaction was effected pursuant to a trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.02 per share to $22.22 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction. Row 4 · 2025-07-16 · Exercise / conversion · Acquired 51,043 · Balance 95,043 Row 5 · 2025-07-16 · Sale · Disposed 51,043 · Balance 44,000 F1: This transaction was effected pursuant to a trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.88 per share to $21.56 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.90 · Expires 2033-01-01 | Direct | 213,745 |
Reported balance
After 2025-07-15 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2025-07-15 · Exercise / conversion · Disposed 47,569 · Balance 213,745 F5: The option was granted on January 1, 2023. 25% of the shares underlying the option vested on the one-year anniversary of the vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.90 · Expires 2033-01-01 | Direct | 162,702 |
Reported balance
After 2025-07-16 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2025-07-16 · Exercise / conversion · Disposed 51,043 · Balance 162,702 F5: The option was granted on January 1, 2023. 25% of the shares underlying the option vested on the one-year anniversary of the vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was effected pursuant to a trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.02 per share to $22.01 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.02 per share to $22.22 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.88 per share to $21.56 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
F5: The option was granted on January 1, 2023. 25% of the shares underlying the option vested on the one-year anniversary of the vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 07, 2025 Filed Jan 7, 2025 22:10 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | GrantOrdinary Shares | 44,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-002979 · ownership.xml · nonDerivative · entry 1 Kling Douglas F · CIK 0001699022 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,000 F1 · shares: Represents restricted stock units (RSUs), each representing a contingent right to receive one ordinary share. 1/3 of the RSUs will vest on each of the first, second and third anniversaries of the vesting start date, subject to the Reporting Person's continued service through each such date. F2 · price: Each RSU was granted on January 7, 2025 for no consideration. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 22:57 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | GrantOption (right to buy) · Derivative | 250,000 | $0.00 Strike: $25.96 | $0.00 |
DisclosureSEC source: 0000950170-25-002374 · ownership.xml · derivative · entry 1 Kling Douglas F · CIK 0001699022 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,000 Underlying: Ordinary Shares · 250,000 shares Expires 2035-01-02 F1 · derivative.exercise_date: 25% of the shares underlying the option will vest on January 2, 2026, the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date. Read SEC document |
| January 01, 2024 Filed Jan 3, 2024 22:21 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | GrantOption (right to buy) · Derivative | 323,771 | $0.00 Strike: $11.17 | $0.00 |
DisclosureSEC source: 0000950170-24-001141 · ownership.xml · derivative · entry 1 Kling Douglas F · CIK 0001699022 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 323,771 Underlying: Ordinary Shares · 323,771 shares Expires 2034-01-01 F1 · derivative.exercise_date: 25% of the shares underlying the option will vest on January 1, 2025, the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.